LLY

913

-2.42%↓

JNJ

186.67

+0.53%↑

UNH

317.28

-3.01%↓

NVS

126.3

+0.04%↑

ABT

125.48

+1.11%↑

LLY

913

-2.42%↓

JNJ

186.67

+0.53%↑

UNH

317.28

-3.01%↓

NVS

126.3

+0.04%↑

ABT

125.48

+1.11%↑

LLY

913

-2.42%↓

JNJ

186.67

+0.53%↑

UNH

317.28

-3.01%↓

NVS

126.3

+0.04%↑

ABT

125.48

+1.11%↑

LLY

913

-2.42%↓

JNJ

186.67

+0.53%↑

UNH

317.28

-3.01%↓

NVS

126.3

+0.04%↑

ABT

125.48

+1.11%↑

LLY

913

-2.42%↓

JNJ

186.67

+0.53%↑

UNH

317.28

-3.01%↓

NVS

126.3

+0.04%↑

ABT

125.48

+1.11%↑

Search

Charles River Laboratories International Inc

Abrir

SetorSaúde

170.32 -1.82

Visão Geral

Variação de preço das ações

24h

Atual

Mín

165.17

Máximo

171.93

Indicadores-chave

By Trading Economics

Rendimento

27M

53M

Vendas

48M

1B

P/E

Médio do Setor

592.3

77.256

Margem de lucro

5.105

Funcionários

18,700

EBITDA

37M

221M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+12.92% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

555M

8.8B

Abertura anterior

172.14

Fecho anterior

170.32

Sentimento de Notícias

By Acuity

24%

76%

55 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de nov. de 2025, 23:38 UTC

Ganhos

OCBC Posts Steady Third-Quarter Net Profit, Drop in Net Interest Income

6 de nov. de 2025, 23:00 UTC

Ganhos

Macquarie's First-Half Profit Grows 2.7%, Missing Forecasts -- Update

6 de nov. de 2025, 22:19 UTC

Ganhos
Grandes Movimentos do Mercado

Block Shares Slide After 3Q Results Miss Estimates

6 de nov. de 2025, 21:53 UTC

Ganhos

Macquarie's First-Half Profit Grows 2.7%, Missing Forecasts

6 de nov. de 2025, 23:45 UTC

Ganhos

Wheaton Precious Metals 3Q Sales $476M >WPM

6 de nov. de 2025, 23:45 UTC

Ganhos

Wheaton Precious Metals 3Q Adj EPS 61.8c >WPM

6 de nov. de 2025, 23:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de nov. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Fall After U.S. Tech Stocks Drop

6 de nov. de 2025, 23:45 UTC

Ganhos

Wheaton Precious Metals 3Q EPS 80.7c >WPM

6 de nov. de 2025, 23:38 UTC

Conversa de Mercado

Gold Edges Higher Amid Worrisome Signs for U.S. Economy -- Market Talk

6 de nov. de 2025, 23:15 UTC

Ganhos

Kakao 3Q Net Profit Beat FactSet-Compiled Consensus

6 de nov. de 2025, 23:14 UTC

Ganhos

Kakao 3Q Net KRW192.86B Vs. Net KRW78.51B >035720.SE

6 de nov. de 2025, 23:14 UTC

Ganhos

Kakao 3Q Oper Pft KRW208.05B Vs. Pft KRW130.53B >035720.SE

6 de nov. de 2025, 23:13 UTC

Ganhos

Kakao 3Q Rev KRW2.087T Vs. KRW1.921T >035720.SE

6 de nov. de 2025, 23:08 UTC

Ganhos

Oversea-Chinese Banking Corp. 3Q Total Income S$3.80B Vs. S$3.80B >O39.SG

6 de nov. de 2025, 23:08 UTC

Ganhos

Oversea-Chinese Banking Corp. 3Q Noninterest Income S$1.57B Vs. S$1.37B >O39.SG

6 de nov. de 2025, 23:07 UTC

Ganhos

Oversea-Chinese Banking Corp. 3Q Net S$1.98B Vs. Net S$1.97B >O39.SG

6 de nov. de 2025, 23:07 UTC

Ganhos

Suzano 3Q Rev BRL12.2B >SUZ

6 de nov. de 2025, 22:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Wheaton Precious Metals to Pay Waterton Gold $670M Up Front

6 de nov. de 2025, 22:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Wheaton Precious Metals to Buy Gold Stream on Spring Valley Project Located in Nevada >WPM

6 de nov. de 2025, 22:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific and Norfolk Southern Provide Supplemental Disclosures to Joint Proxy Statement About Merger

6 de nov. de 2025, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

At Bank of America's Investor Day, M&A Hints, Would-Be CEOs, and AI Pitches -- Barrons.com

6 de nov. de 2025, 22:13 UTC

Ganhos

Fairfax Financial 3Q Rev $8.27B >FFH.T

6 de nov. de 2025, 22:02 UTC

Ganhos

Century Aluminum 3Q Sales $632.2M >CENX

6 de nov. de 2025, 22:02 UTC

Ganhos

Century Aluminum 3Q Adj EPS 56c >CENX

6 de nov. de 2025, 21:53 UTC

Ganhos

DraftKings Stock Sinks on Disappointing Results -- Barrons.com

6 de nov. de 2025, 21:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Display: Portfolio Includes More Than 300 Issued and Pending Patents Worldwide, Covering More Than 110 Unique Patent Families >OLED

6 de nov. de 2025, 21:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Display Corp to Acquire Emissive OLED Patent Assets From Merck KGaA, Darmstadt, Germany

6 de nov. de 2025, 21:50 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

6 de nov. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

12.92% parte superior

Previsão para 12 meses

Média 189.36 USD  12.92%

Máximo 225 USD

Mínimo 165 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

7

Comprar

6

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

55 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat